FFF Enterprises: BioSupply Trends Newsletter
Wednesday, Aug 17, 2016

Flu Vaccine Reduces Heart and Breathing Problems in Diabetics

 

In this Issue

•  IVIG/Albumin Supply Index
•  Open Market Pricing
•  New Products from FFF
•  Current Medicare
IVIG / SCIG Rates
•  Resources
•  Subscribe to IG Living and BioSupply Trends Quarterly
 

A study has found that individuals with type 2 diabetes who receive the influenza (flu) vaccine may be less likely to be hospitalized for cardiovascular or respiratory problems. [ read more ]

Idelvion Prevents Bleeds and Reduces Drug Consumption in Hemophilia B Patients

Results from the Phase III PROLONG-9FP ongoing extension clinical development program evaluating the long-term efficacy and safety of Idelivion (coagulation factor IX [recombinant], albumin fusion protein) showed that extended prophylaxis treatment regimens effectively prevented bleeds while also reducing overall IDELVION consumption. [ read more ]

New Plant-Derived Drug May Stop the Progression of MS

An international team of researchers has developed a new plant-derived drug, T20K (extracted from the medicinal plant Oldenlandia affinis), that shows it can stop the progression of multiple sclerosis. [ read more ]

Industry News

 
 

From Merck

The U.S. Food and Drug Administration has approved Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, at a fixed dose of 200 mg every three weeks for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy. [ read more ]

From CSL Behring

CSL Behring’s Berinert (C1 esterase inhibitor [human]) has been approved by the U.S. Food and Drug Administration to treat hereditary angioedema (HAE) attacks in pediatric patients, which expands the use of Berinert into all age groups, making it the first and only approved HAE treatment available to patients under 12 years of age. [ read more ]

From Sandoz

In July, Sandoz announced the U.S. market introduction of rosuvastatin calcium tablets, a generic version of Crestor by AstraZenica Pharmaceuticals LP, to be used along with diet to lower the level of LDL, increase the level of HDL and/or lower the level of triglycerides. [ read more ]

IVIG & Albumin Supply Index

 
 

Featured Products of the Month

 
HyperRHO S/D
 

HyperRHO® S/D

HyperRHO S/D is a RhO(D) immune globulin (Human) for intramuscular use indicated for: 1) pregnancy and other obstetric conditions; and 2) transfusion. HyperRHO S/D Full Dose is recommended for the prevention of Rh hemolytic disease of the newborn by its administration to the RhO(D) negative mother within 72 hours after birth of an Rh0(D) positive infant. HyperRHO S/D Mini-Dose is recommended to prevent the isoimmunization of RhO(D) negative women at the time of spontaneous or induced abortion of up to 12 weeks' gestation. For transfusion, HyperRHO S/D is used to prevent isoimmunization in Rh0(D) negative individuals who have been transfused with Rh0(D) positive red blood cells or blood components containing red blood cells. [ read more ]
 
 
HyperRAB S/D
 

HyperRAB® S/D

HyperRAB S/D is a rabies immune globulin (Human) for intramuscular use. The rabies vaccine and HyperRAB S/D should be given to all persons suspected of exposure to rabies with one exception: Persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine. HyperRAB S/D should be administered as promptly as possible after exposure, but can be administered up to the eighth day after the first dose of vaccine is given. [ read more ]

 

What's New at FFF

CEFEPIME  (WG Critical Care)

Cefepime (intravenous infusion) is indicated for the treatment of several types of bacterial infections of the lungs, skin, abdomen and urinary tract.

For more information about Cefepime, go to biosupply.fffenterprises.com

SOTRADECOL  (Mylan)

Sotradecol injection is indicated for the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves.

For more information about Sotradecol, go to biosupply.fffenterprises.com

ENTYVIO  (Takeda)

Entyvio (vedolizumab) is indicated for treatment of adults with 1) moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to or demonstrated dependence on corticosteroids to: induce and maintain clinical response or remission, improve endoscopic appearance of the mucosa or achieve corticosteroid-free remission; and 2) moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to or were intolerant to a TNF blocker or immunomodulator; or had an inadequate response with, were intolerant to or demonstrated dependence on corticosteroids to: achieve clinical response, clinical remission or corticosteroid-free remission.

For more information about Entyvio, go to biosupply.fffenterprises.com

ARIPIPRAZOLE  (Apotex)

Aripiprazole tablets are an atypical antipsychotic used to treat schizophrenia, bipolar disorder, major depressive disorder and irritability associated with autism.

For more information about Aripiprazole, go to biosupply.fffenterprises.com
*Call for eligibility through your GPO affiliation.

VERAPAMIL HCI INJECTION  (Exela Pharma Sciences)

Verapamil hydrochloride injectable (HCI) is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) that works by relaxing the muscles of the heart and blood vessels. It is indicated for the treatment of supraventricular tachyarrhythmias, including 1) rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardia, including those associated with accessory bypass tracts (Wolf-Parkinson-White [WPW] and Lown-Ganong-Levine [LGL] syndromes), and 2) temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation, except when the atrial flutter and/or fibrillation are associated with accessory bypass tracts (Wolf-Parkinson-White [WPS] and Lown-Ganong-Levine [LGL] syndromes).

For more information about Verapamil HCI, go to biosupply.fffenterprises.com
*Call for eligibility through your GPO affiliation.

OMIDRIA  (Omeros)

Omidria is an alpha 1-adrenergic receptor agonist and nonselective cyclooxygenase inhibitor that is added to ophthalmic irrigation solution used during cataract surgery or intraocular lens replacement. It is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

For more information about Omidria, go to biosupply.fffenterprises.com

These products can be ordered from FFF Enterprise's BioSupply Online Ordering System or by calling
Wow! Customer Care at (800) 843-7477.

Current Medicare IVIG / SCIG Rates

Rates per gram are effective July 1, 2016, through September 30, 2016.

Product J Codes ASP + 6%
(before sequester)
ASP + 4.3%*
(after sequester)
IVIG
Bivigam J1556 $74.81 $73.61
Carimune NF J1566 $68.07 $66.97
Flebogamma J1572 $75.78 $74.56
Gammagard S/D J1566 $68.07 $66.97
Gammaplex J1557 $73.86 $72.67
Octagam J1568 $79.55 $78.28
Privigen J1459 $76.47 $75.24
SCIG
Hizentra J1559 $98.35 $96.77
HyQvia J1575 $129.98 $127.90
IVIG / SCIG
Gammagard Liquid J1569 $80.00 $78.72
Gammaked J1561 $81.80 $80.49
Gamunex-C J1561 $81.80 $80.49

*Reflects 2% sequestration reduction applied to 80% Medicare payment portion as required under Budget Control Act of 2011.

 

Resources

FFF customers may order the following complementary resources to help you with your practice:

•  IG Immune Globulin (Human)
•  Hyperimmune Globulins
•  Anti-Inhibitor, Factor VIIa & IX
•  Factor VIII & von Willebrand Factor
•  Seasonal Influenza Vaccine

Subscribe to IG Living

IG Living is the only magazine for the immune globulin (IG) community for patients who suffer from chronic illness and their caregivers.

Subscribe to BioSupply
Trends Quarterly

BioSupply Trends Quarterly magazine is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace.

Home | About | Advertise | Subscribe | Contact – ©2016 FFF Enterprises, Inc.
This email was sent by: %%Member_Busname%%, %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
Manage preferences: Privacy Policy, Update Profile, Unsubscribe.